INSERTING and REPLACING SBC Medical Group Holdings Announces Second Quarter 2025 Financial Results

IRVINE, Calif.--(BUSINESS WIRE)-- Insert after the second paragraph, 9th bullet: First Half 2025 Highlights.

The updated release reads: 

SBC MEDICAL GROUP HOLDINGS ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS

SBC Medical Group Holdings Incorporated (NASDAQ: SBC, “SBC Medical” or the “Company”), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced its financial results for the second quarter of fiscal year 2025 (three months ended June 30, 2025) and for the first half of fiscal year 2025 (six months ended June 30, 2025).

Second Quarter 2025 Highlights

• Total revenues were $43 million, representing an 18% year-over-year decrease.
• Income from operations was $15 million, representing a 47% year-over-year decrease.
• Net Income attributable to SBC Medical Group was $2.5 million, representing an 87% year-over-year decrease.
• Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.02 for the three months ended June 30, 2025, compared to $0.20 in the same period of 2024.
• EBITDA¹, which is calculated by adding depreciation and amortization expense and impairment loss to income from operations was $15 million, representing a 46% year-over-year decrease. EBITDA margin¹ was 35% for the second quarter of 2025, compared to 53% for second quarter of 2024.
• Return on equity, which is defined as net income attributable to the Company divided by the average of shareholder’s equity as of June 30, 2025, was 4% representing a year-over-year decrease of 44 percentage points.
• Number of Franchise Locations² was 259 as of June 30, 2025, representing an increase of 36 locations from June 30, 2024.
• Number of customers³ in the last twelve months ended June 30, 2025, was 6.31 million, representing a 14% year-over-year increase.
• Repeat rate for customers⁴ who visited franchisee’s clinics twice or more was 72%.

First Half 2025 Highlights

• Total revenues were $91 million, representing a 16% year-over-year decrease.
• Income from operations was $39 million, representing a 25% year-over-year decrease.
• Net Income attributable to SBC Medical Group was $24 million, representing a 36% year-over-year decrease.
• Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.23 for the six months ended June 30, 2025, compared to $0.40 in the same period of 2024.
• EBITDA¹, which is calculated by adding depreciation and amortization expense and impairment loss to income from operations was $40 million, representing a 25% year-over-year decrease. EBITDA margin¹ was 44% for the first half of 2025, compared to 50% for first half of 2024.

Yoshiyuki Aikawa, Chairman and Chief Executive Officer of SBC Medical, said, “ As anticipated and signaled in our prior guidance, Q2 2025 reflected strategic shifts aimed to position SBC Medical for long-term competitiveness and scalability. Total revenue declined 18% year-over-year to $43 million, primarily due to the completed discontinuation of our staffing business, targeted divestitures to streamline our operations, and revision of fee structure. We are executing our strategic plan with precision, as evidenced by our network of 259 Franchise Locations as of June 30, 2025 and 6.31 million visits over the last twelve months, demonstrating a scale that is unmatched in Japan. Our high repeat rate underscores the strength of our Shonan Beauty Clinic brand. Japan’s consumer discretionary market faces challenges, including restrained growth due to trade restrictions and cautious consumer spending. Despite these headwinds, we are successfully advancing key initiatives, including the acquisition of MB career lounge to enhance our management support services and the joining of JUN CLINIC to our network, which boasts a high average spend per customer. Looking ahead, we remain confident in our strategic roadmap, focused on optimizing our franchise model, capturing growth opportunities, transitioning to higher-margin models, and delivering lasting value to our shareholders.”

Second Quarter 2025 Financial Results

Total revenues were $43 million, a decrease of 18% year-over-year, primarily due to a revised fee structure for franchising services implemented starting from April 2025, the discontinuation staffing services business, and divestiture of SNA and Kijimadaira, partially offset by growth in procurement, rental services, and other revenue streams.

Net income attributable to SBC Medical Group for the three months ended June 30, 2025 was $2.5 million, compared to $18.5 million in the same period of 2024. The decrease was largely attributed to unfavorable changes in other income and expenses, primarily due to higher foreign exchange losses.

EBITDA¹ was $15 million, a decrease of 46% year-over-year, primarily due to lower revenue following the termination of the staffing services business, the deconsolidation of SNA and Kijimadaira, and revision of fee structure.

Conference Call

The Company will hold a conference call on Wednesday, August 13, 2025 at 8:30 am Eastern Time (or Wednesday, August 13, 2025 at 9:30 pm Japan Time) to discuss the financial results and take questions live.

Please register in advance of the conference using the link provided below.
https://edge.media-server.com/mmc/p/ukc9sp9j/lan/en/

It will automatically direct you to the registration page of “SBC Q2 2025 Financial Results Presentation.”. Please follow the steps to enter your registration details, then click “Submit.”. Upon registration, you will be able to access the dedicated Conference Call viewing site. In addition to viewing the conference call, this site provides access to information about the speakers as well as past investor relations materials.

Starting 10 minutes before the conference call begins, you will be able to view the earnings presentation materials on the site. The materials will also be available for download.

A replay of the conference call will be accessible until August 13, 2026.

Additionally, the earnings release, accompanying slides, and an archived webcast of this conference call will be available at the Company’s Investor Relations website at https://ir.sbc-holdings.com/

About SBC Medical

SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchise clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchise clinic customers, assistance with franchise employee housing rentals and facility rentals, construction and design of franchise clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchise clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchise clinic’s customer rewards program (customer loyalty point program), and payment tools for the franchise clinics.

For more information, visit https://sbc-holdings.com/

Use of Non-GAAP Financial Measures

The Company uses non-GAAP measures, such as EBITDA and EBITDA margin, in evaluating its operating results and for financial and operational decision-making purposes. The Company believes that the non-GAAP financial measures help identify underlying trends in its business. The Company believes that the non-GAAP financial measures provide useful information about the Company’s results of operations, enhance the overall understanding of the Company’s past performance and future prospects and allow for greater visibility with respect to key metrics used by the Company’s management in its financial and operational decision-making.

The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The non-GAAP financial measures have limitations as analytical tools, and when assessing the Company’s operating performance, cash flows or liquidity, investors should not consider them in isolation, or as a substitute for net loss, cash flows provided by operating activities or other consolidated statements of operations and cash flows data prepared in accordance with U.S. GAAP.

The Company mitigates these limitations by reconciling the non-GAAP financial measures to the most comparable U.S. GAAP performance measures, all of which should be considered when evaluating the Company’s performance.

For more information on the non-GAAP financial measures, please see the table captioned “Unaudited Reconciliations of GAAP and Non-GAAP Results.”

Forward Looking Statements

This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, the Company’s financial performance; growth in revenue and earnings; business prospects and opportunities; and capital deployment plans and liquidity. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.

1 EBITDA and EBITDA Margin are non-GAAP financial measures. For more information on non-GAAP financial measures, please see the section “Use of Non-GAAP Financial Measures” and the table captioned “Unaudited Reconciliations of GAAP and Non-GAAP Results.”

2 The figures take into accounts of the franchising of SBC brand clinics, Rize Clinic, Gorilla Clinic, AHH, JUN CLINIC

3 The number of customers takes into account customers of SBC brand clinics, Rize Clinic and Gorilla Clinic, AHH Clinic but does not take account of customers of JUN CLINIC, but excluding free counseling. The applicable periods are from July 1, 2024, to June 30, 2025

4 The figures include franchising of SBC brand clinics, Rize Clinic, and Gorilla Clinic, but does not take account of customers of AHH clinics and JUN CLINIC excluding free counseling. The percentage of customers who visited our franchisee’s clinics twice or more.

SBC MEDICAL GROUP HOLDINGS INCORPORATED
UNAUDITED CONSOLIDATED BALANCE SHEETS

		June 30, 2025				December 31, 2024
ASSETS
Current assets:
Cash and cash equivalents		$	152,740,882			$	125,044,092
Accounts receivable			2,350,368				1,413,433
Accounts receivable – related parties			48,920,843				28,846,680
Inventories			1,705,237				1,494,891
Finance lease receivables, current – related parties			9,128,931				5,992,585
Customer loans receivable, current			10,552,623				10,382,537
Prepaid expenses and other current assets			14,051,746				11,276,802
Other receivables – related parties			1,891,408				—
Total current assets			241,342,038				184,451,020
Non-current assets:
Property and equipment, net			8,058,016				8,771,902
Intangible assets, net			1,584,543				1,590,052
Long-term investments, net			3,593,087				3,049,972
Goodwill, net			5,011,511				4,613,784
Cryptocurrencies			535,882				—
Finance lease receivables, non-current – related parties			13,197,979				8,397,582
Operating lease right-of-use assets			4,583,393				5,267,056
Finance lease right-of-use assets			516,932				—
Deferred tax assets			2,343,302				9,798,071
Customer loans receivable, non-current			5,934,636				5,023,551
Long-term prepayments			1,755,292				1,745,801
Long-term investments in MCs – related parties			19,381,422				17,820,910
Other assets			7,461,224				15,553,453
Total non-current assets			73,957,219				81,632,134
Total assets		$	315,299,257			$	266,083,154
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable		$	16,290,206			$	13,875,179
Accounts payable – related parties			3,245,989				659,044
Current portion of long-term loans			69,420				96,824
Notes and other payables, current – related parties			3,272,048				26,255
Advances from customers			512,123				820,898
Advances from customers – related parties			10,333,007				11,739,533
Income tax payable			14,133,163				18,705,851
Operating lease liabilities, current			3,623,871				4,341,522
Finance lease liabilities, current			161,340				—
Accrued liabilities and other current liabilities			6,229,797				8,103,194
Due to related party			2,810,647				2,823,590
Total current liabilities			60,681,611				61,191,890

SBC MEDICAL GROUP HOLDINGS INCORPORATED
UNAUDITED CONSOLIDATED BALANCE SHEETS — (Continued)

		June 30, 2025				December 31, 2024
Non-current liabilities:
Long-term loans			7,031,506				6,502,682
Notes and other payables, non-current – related parties			—				5,334
Deferred tax liabilities			353,517				926,023
Operating lease liabilities, non-current			1,208,516				1,241,526
Finance lease liabilities, non-current			164,721				—
Other liabilities			1,206,815				1,193,541
Total non-current liabilities			9,965,075				9,869,106
Total liabilities			70,646,686				71,060,996
Stockholders’ equity:
Preferred stock ($0.0001 par value, 20,000,000 shares authorized; no shares issued and outstanding as of June 30, 2025 and December 31, 2024)			—				—
Common stock ($0.0001 par value, 400,000,000 shares authorized, 103,881,251 and 103,020,816 shares issued, 103,098,442 and 102,750,816 shares outstanding as of June 30, 2025 and December 31, 2024, respectively)			10,388				10,302
Additional paid-in capital			72,196,114				62,513,923
Treasury stock (at cost, 782,809 and 270,000 shares as of June 30, 2025 and December 31, 2024, respectively)			(5,115,262	)			(2,700,000	)
Retained earnings			213,423,693				189,463,007
Accumulated other comprehensive loss			(35,922,942	)			(54,178,075	)
Total SBC Medical Group Holdings Incorporated stockholders’ equity			244,591,991				195,109,157
Non-controlling interests			60,580				(86,999	)
Total stockholders’ equity			244,652,571				195,022,158
Total liabilities and stockholders’ equity		$	315,299,257			$	266,083,154

The accompanying notes are an integral part of these unaudited consolidated financial statements.



SBC MEDICAL GROUP HOLDINGS INCORPORATED
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND
COMPREHENSIVE INCOME

		For the Three Months Ended June 30,								For the Six Months Ended June 30,
		2025				2024				2025				2024
Revenues, net – related parties		$	38,944,898			$	51,039,038			$	84,202,043			$	101,509,245
Revenues, net			4,413,949				2,063,042				6,485,505				6,400,877
Total revenues, net			43,358,847				53,102,080				90,687,548				107,910,122
Cost of revenues (including cost of revenues from related parties of $4,669,602 and $3,616,103 for the three months ended June 30, 2025 and 2024, and $8,126,530 and $5,413,462 for the six months ended June 30, 2025 and 2024, respectively)			13,348,270				13,682,405				22,943,887				28,971,072
Gross profit			30,010,577				39,419,675				67,743,661				78,939,050
Operating expenses:
Selling, general and administrative expenses (including selling, general and administrative expenses from related parties of $415,767 and nil for the three months ended June 30, 2025 and 2024, and $415,767 and nil for the six months ended June 30, 2025 and 2024, respectively)			15,456,385				12,129,115				28,987,395				27,187,605
Total operating expenses			15,456,385				12,129,115				28,987,395				27,187,605
Income from operations			14,554,192				27,290,560				38,756,266				51,751,445
Other income (expenses):
Interest income			22,882				11,644				78,215				29,333
Interest expense			(49,651	)			(7,424	)			(55,858	)			(10,432	)
Other income			33,771				306,291				185,099				655,972
Other expenses			(1,132,465	)			(514,636	)			(2,829,724	)			(1,951,292	)
Gain on redemption of life insurance policies			—				—				8,746,138				—
Change in fair value of cryptocurrencies			111,632				—				111,632				—
Gain on disposal of subsidiary			—				—				—				3,813,609
Total other income (expenses)			(1,013,831	)			(204,125	)			6,235,502				2,537,190
Income before income taxes			13,540,361				27,086,435				44,991,768				54,288,635
Income tax expense			11,100,509				8,529,110				21,059,966				16,981,094
Net income			2,439,852				18,557,325				23,931,802				37,307,541
Less: net income (loss) attributable to non-controlling interests			(18,388	)			72,917				(28,884	)			65,381
Net income attributable to SBC Medical Group Holdings Incorporated		$	2,458,240			$	18,484,408			$	23,960,686			$	37,242,160
Other comprehensive income (loss):
Foreign currency translation adjustment		$	8,623,269			$	(9,046,549	)		$	18,431,596			$	(19,240,401	)
Total comprehensive income			11,063,121				9,510,776				42,363,398				18,067,140
Less: comprehensive income (loss) attributable to non-controlling interests			184,411				22,000				147,579				(70,000	)
Comprehensive income attributable to SBC Medical Group Holdings Incorporated		$	10,878,710			$	9,488,776			$	42,215,819			$	18,137,140
Net income per share attributable to SBC Medical Group Holdings Incorporated*
Basic and diluted		$	0.02			$	0.20			$	0.23			$	0.40
Weighted average shares outstanding*
Basic and diluted			103,507,249				94,192,433				103,392,580				94,192,433

*	Retrospectively restated for effect of reverse recapitalization on September 17, 2024.

The accompanying notes are an integral part of these unaudited consolidated financial statements.



SBC MEDICAL GROUP HOLDINGS INCORPORATED
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS

		For the Six Months Ended June 30,
		2025				2024
CASH FLOWS FROM OPERATING ACTIVITIES
Net income		$	23,931,802			$	37,307,541
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization expense			1,264,405				1,849,422
Non-cash lease expense			2,185,744				1,923,890
Provision for credit losses			283,752				62,804
Fair value change of long-term investments			384,523				1,045,557
Gain on disposal of subsidiary			—				(3,813,609	)
Gain on redemption of life insurance policies			(8,746,138	)			—
Gain on disposal of property and equipment			(10,804	)			(902	)
Change in fair value of cryptocurrencies			(111,632	)			—
Deferred income taxes			7,452,983				(3,322,728	)
Changes in operating assets and liabilities:
Accounts receivable			(789,577	)			(1,423,412	)
Accounts receivable – related parties			(17,039,113	)			5,843,499
Inventories			(717,972	)			561,921
Finance lease receivables – related parties			(6,482,967	)			(1,759,556	)
Customer loans receivable			8,081,703				7,521,267
Prepaid expenses and other current assets			(1,349,225	)			(1,488,347	)
Long-term prepayments			211,988				(41,412	)
Other assets			85,907				(1,007,431	)
Accounts payable			1,165,217				(8,960,556	)
Accounts payable – related parties			2,455,865				—
Notes and other payables – related parties			(5,031,570	)			(5,101,368	)
Advances from customers			(369,616	)			(755,977	)
Advances from customers – related parties			(2,363,891	)			(4,663,233	)
Income tax payable			(6,030,526	)			5,462,133
Operating lease liabilities			(2,275,398	)			(1,998,196	)
Accrued liabilities and other current liabilities			(2,508,035	)			(4,444,172	)
Other liabilities			(88,593	)			77,625
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES			(6,411,168	)			22,874,760
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment			(560,431	)			(1,565,333	)
Purchase of convertible note			—				(1,700,000	)
Prepayments for property and equipment			(705,351	)			—
Advances to related parties			—				(617,804	)
Payments made on behalf of related parties			(1,836,541	)			(5,245,990	)
Purchase of long-term investments			(652,555	)			—
Purchase of cryptocurrencies			(424,250	)			—
Long-term loans to others			(13,134	)			(62,489	)
Repayments from related parties			70,000				555,000
Repayments from others			56,307				44,748
Proceeds from redemption of life insurance policies			17,735,717				—
Disposal of subsidiary, net of cash disposed of			—				(815,819	)
Proceeds from disposal of property and equipment			1,728,236				1,971
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES			15,397,998				(9,405,716	)

SBC MEDICAL GROUP HOLDINGS INCORPORATED
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS — (Continued)

		For the Six Months Ended June 30,
		2025				2024
CASH FLOWS FROM FINANCING ACTIVITIES
Borrowings from related parties			15,000				—
Repayments of long-term loans			(74,256	)			(59,217	)
Repayments of finance lease liabilities			(278,097	)			—
Repayments to related parties			(27,943	)			(50,124	)
Repurchase of common stock			(2,415,262	)			—
Deemed contribution in connection with price modification on disposal of property and equipment			9,682,277				—
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES			6,901,719				(109,341	)
Effect of exchange rate changes			11,808,241				(12,679,865	)
NET CHANGE IN CASH AND CASH EQUIVALENTS			27,696,790				679,838
CASH AND CASH EQUIVALENTS AS OF THE BEGINNING OF THE PERIOD			125,044,092				103,022,932
CASH AND CASH EQUIVALENTS AS OF THE END OF THE PERIOD		$	152,740,882			$	103,702,770
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest expense		$	55,858			$	10,432
Cash paid for income taxes, net		$	19,637,454			$	16,191,178
NON-CASH INVESTING AND FINANCING ACTIVITIES
Property and equipment transferred from long-term prepayments		$	246,188			$	—
Operating lease right-of-use assets obtained in exchange for operating lease liabilities		$	104,437			$	—
Finance lease right-of-use assets obtained in exchange for finance lease liabilities		$	612,466			$	—
Remeasurement of operating lease liabilities and right-of-use assets due to lease modifications		$	1,160,680			$	1,376,034
Payables to related parties in connection with loan services provided		$	8,175,342			$	16,085,387
Issuance of common stock as incentive shares		$	86			$	—

The accompanying notes are an integral part of these unaudited consolidated financial statements.



RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

SBC MEDICAL GROUP HOLDINGS INCORPORATED
Unaudited Reconciliations of GAAP and Non-GAAP Results

		For the Three Months Ended June 30,								For the Six Months Ended June 30,
		2025				2024				2025				2024
Total revenues, net		$	43,358,847			$	53,102,080			$	90,687,548				107,910,122
Income from operations			14,554,192				27,290,560				38,756,266				51,751,445
Depreciation and amortization expense			636,101				830,945				1,264,405				1,849,422
EBITDA			15,190,293				28,121,505				40,020,671				53,600,867
EBITDA margin			35	%			53	%			44	%			50	%

The accompanying notes are an integral part of these unaudited consolidated financial statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250813939975/en/

In Asia:

SBC Medical Group Holdings Incorporated

Hikaru Fukui / Head of Investor Relations

E-mail: ir@sbc-holdings.com

In the US:

ICR LLC

Bill Zima / Managing Partner

Email: bill.zima@icrinc.com

Source: SBC Medical Group Holdings Incorporated